Incyte | INCY - Kapitał Własny I Rezerwy





Kapitał Własny I Rezerwy Zmiana Data
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
Agenus USD -221.22M 49.89M 2026-03
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Amgen USD 9.19B 532M 2026-03
BioCryst Pharmaceuticals USD -553.84M 434.69M 2026-03
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Eli Lilly USD 31.2B 4.66B 2026-03
Exelixis USD 1.94B 225.57M 2026-03
Gilead Sciences USD 23.52B 897M 2026-03
Incyte USD 5.62B 455.37M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
MacroGenics USD 21.2M 34.39M 2026-03
Merck USD 45.88B 6.73B 2026-03
Moderna USD 7.41B 1.24B 2026-03
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Novartis USD 38.93B 7.2B 2026-03
Novartis USD 46.13B 1.8B 2025-12
Pfizer USD 90.1B 3.63B 2026-03
PTC Therapeutics USD -180.46M 24.85M 2026-03
Puma Biotechnology USD 115.27M 10.55M 2025-09
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03